Cargando…

Clinical Efficacy and Safety of Psoriasis Treatments in Patients with Concomitant Metabolic Syndrome: A Narrative Review

Metabolic syndrome (MetS) is well recognized as a frequent comorbidity of psoriasis with important implications for efficacy and safety of psoriasis treatment. The presence of concomitant MetS is associated with decreased efficacy response to biologic treatment for psoriasis in observational studies...

Descripción completa

Detalles Bibliográficos
Autores principales:	Merola, Joseph F., Kavanaugh, Arthur, Lebwohl, Mark G., Gniadecki, Robert, Wu, Jashin J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515257/ https://www.ncbi.nlm.nih.gov/pubmed/36008702 http://dx.doi.org/10.1007/s13555-022-00790-2

Ejemplares similares

Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis
por: Wu, J.J., et al.
Publicado: (2022)

Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence
por: Wu, Jashin J., et al.
Publicado: (2020)

Correction to: Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence
por: Wu, Jashin J., et al.
Publicado: (2020)

US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey
por: Lebwohl, Mark G., et al.
Publicado: (2015)

Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5‐year data from reSURFACE 1 and reSURFACE 2
por: Fernandez, A.P., et al.
Publicado: (2022)

Subcutaneous methotrexate for symptomatic control of severe recalcitrant psoriasis: safety, efficacy, and patient acceptability
por: Manalo, Iviensan F, et al.
Publicado: (2015)

Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review
por: Blauvelt, Andrew, et al.
Publicado: (2023)

Malignancy Rates in Brodalumab Clinical Studies for Psoriasis
por: Gottlieb, Alice, et al.
Publicado: (2020)

Efficacy and safety of secukinumab over 52 weeks in Chinese psoriasis patients with concomitant psoriatic arthritis
por: Cai, Lin, et al.
Publicado: (2021)

Psoriasis: Overview and Diagnosis
por: Kimmel, Grace W., et al.
Publicado: (2018)

Skin Patterning in Psoriasis by Spatial Interactions between Pathogenic Cytokines
por: Ringham, Lee, et al.
Publicado: (2019)

Efficacy and safety of ustekinumab in adolescents
por: Kellen, Roselyn, et al.
Publicado: (2016)

Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits
por: Lebwohl, Mark G., et al.
Publicado: (2021)

Biologic Drug Survival in Psoriasis: A Systematic Review & Comparative Meta-Analysis
por: Mourad, Ahmed I., et al.
Publicado: (2021)

Integrated Safety Analysis on Skin Cancers among Patients with Psoriasis Receiving Ixekizumab in Clinical Trials
por: Smith, Saxon D., et al.
Publicado: (2023)

Psoriasis and Co-morbidity
por: AMIN, Mina, et al.
Publicado: (2020)

Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis
por: Adam, David N., et al.
Publicado: (2022)

Concomitant Interstitial Lung Disease with Psoriasis
por: Ishikawa, Genta, et al.
Publicado: (2019)

Concomitant Interstitial Lung Disease With Psoriasis
por: Kharibam, Prabin, et al.
Publicado: (2022)

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial
por: Blauvelt, Andrew, et al.
Publicado: (2020)

Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population‐based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey
por: van de Kerkhof, P.C.M., et al.
Publicado: (2015)

Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
por: Singh, Sanminder, et al.
Publicado: (2018)

Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study
por: Lebwohl, Mark G., et al.
Publicado: (2019)

Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER‐3 study
por: Lebwohl, M.G., et al.
Publicado: (2019)

Psoriasis and Metabolic Syndrome
por: Malkic Salihbegovic, Eldina, et al.
Publicado: (2015)

Three‐year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial
por: Warren, R. B., et al.
Publicado: (2021)

Reply to: “Biologics for psoriasis during COVID-19 outbreak”
por: Murrell, Dedee F., et al.
Publicado: (2020)

Should biologics for psoriasis be interrupted in the era of COVID-19?
por: Lebwohl, Mark, et al.
Publicado: (2020)

New onset and exacerbation of psoriasis after COVID-19 vaccination
por: Wei, Nancy, et al.
Publicado: (2021)

Clinical Characteristics and Outcomes of Generalized Pustular Psoriasis Flares
por: Choon, Siew Eng, et al.
Publicado: (2023)

Economic Burden of Comorbidities in Patients with Psoriasis in the USA
por: Wu, Jashin J., et al.
Publicado: (2022)

Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis
por: Koutruba, Nora, et al.
Publicado: (2010)

Biologic Treatment in Combination with Lifestyle Intervention in Moderate to Severe Plaque Psoriasis and Concomitant Metabolic Syndrome: Rationale and Methodology of the METABOLyx Randomized Controlled Clinical Trial
por: Pinter, Andreas, et al.
Publicado: (2021)

A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
por: Kirkham, Bruce W., et al.
Publicado: (2023)

Efficacy and safety of curcumin in psoriasis: preclinical and clinical evidence and possible mechanisms
por: Zhang, Shuo, et al.
Publicado: (2022)

Metabolic Comorbidities and Cardiovascular Disease in Pediatric Psoriasis: A Narrative Review
por: Marani, Andrea, et al.
Publicado: (2022)

Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis
por: Gordon, K.B., et al.
Publicado: (2021)

The risk of COVID-19 in patients with psoriasis: A retrospective cohort study
por: Wu, Jashin J., et al.
Publicado: (2022)

Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy
por: Pithadia, Deeti J., et al.
Publicado: (2019)

Psoriasis Prevalence and Severity by Expert Elicitation
por: Papp, Kim A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ghn8veo0e36n6vrj0dh0sg3vul